Efficacy of dostarlimab in recurrent or advanced mismatch Repair-Deficient endometrial Cancer as a Single-Agent therapy: A systematic review and Meta-Analysis.

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

DARU Journal of Pharmaceutical Sciences Pub Date : 2025-07-05 DOI:10.1007/s40199-025-00564-z

Ramazan Rezaei, Hedieh Haji Khodaverdi Khani

{"title":"Efficacy of dostarlimab in recurrent or advanced mismatch Repair-Deficient endometrial Cancer as a Single-Agent therapy: A systematic review and Meta-Analysis.","authors":"Ramazan Rezaei, Hedieh Haji Khodaverdi Khani","doi":"10.1007/s40199-025-00564-z","DOIUrl":null,"url":null,"abstract":"Background: The effectiveness of PD-1 inhibitors for treating endometrial cancer (EC) remains a topic of debate. Guidelines lack consistency regarding the preferred treatments for advanced cases, as well as for patients experiencing metastasis or recurrence. Thus, our goal was to assess the efficacy of Dostarlimab, a PD-1 inhibitor, in EC by incorporating data from clinical trials to create a more comprehensive database.Methods: We conducted a thorough and systematic search of the Scopus, Medline, Embase, and Web of Science databases, identifying all eligible studies on Dostarlimab's efficacy in endometrial cancer.Results: Our data demonstrated that the hazard ratio of OS in the pooled proportion of participants was 43%. The hazard ratio of PFS in the pooled proportion of EC patients was 0.39 (95% CI: 0.31-0.49). The overall analysis generated a probability of remaining in response of 72.71% (95% CI: 60.94-84.49%). In addition, pooling the results from both subgroups of EC patients, including proficient mismatch repair (pMMR) and deficient mismatch repair (dMMR), yielded an ORR of 33.93% (95% CI: 21.49-46.37%) and a DCR of 51.73% (95% CI: 37.0-66.42%). Overall, the deficient mismatch repair group compared to the proficient mismatch repair group showed better outcomes. Finally, the dMMR subgroup showed a median PFS of 7.86 months (95% CI: 4.46-11.26).Conclusion: Dostarlimab demonstrated limited efficacy in patients with pMMR EC, but it represented better outcomes in those with dMMR EC.","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"33 2","pages":"22"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228622/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DARU Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40199-025-00564-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The effectiveness of PD-1 inhibitors for treating endometrial cancer (EC) remains a topic of debate. Guidelines lack consistency regarding the preferred treatments for advanced cases, as well as for patients experiencing metastasis or recurrence. Thus, our goal was to assess the efficacy of Dostarlimab, a PD-1 inhibitor, in EC by incorporating data from clinical trials to create a more comprehensive database.

Methods: We conducted a thorough and systematic search of the Scopus, Medline, Embase, and Web of Science databases, identifying all eligible studies on Dostarlimab's efficacy in endometrial cancer.

Results: Our data demonstrated that the hazard ratio of OS in the pooled proportion of participants was 43%. The hazard ratio of PFS in the pooled proportion of EC patients was 0.39 (95% CI: 0.31-0.49). The overall analysis generated a probability of remaining in response of 72.71% (95% CI: 60.94-84.49%). In addition, pooling the results from both subgroups of EC patients, including proficient mismatch repair (pMMR) and deficient mismatch repair (dMMR), yielded an ORR of 33.93% (95% CI: 21.49-46.37%) and a DCR of 51.73% (95% CI: 37.0-66.42%). Overall, the deficient mismatch repair group compared to the proficient mismatch repair group showed better outcomes. Finally, the dMMR subgroup showed a median PFS of 7.86 months (95% CI: 4.46-11.26).

Conclusion: Dostarlimab demonstrated limited efficacy in patients with pMMR EC, but it represented better outcomes in those with dMMR EC.

查看原文本刊更多论文

多司达单抗治疗复发性或晚期错配修复缺陷子宫内膜癌的疗效：一项系统综述和荟萃分析

背景：PD-1抑制剂治疗子宫内膜癌（EC）的有效性仍然是一个有争议的话题。指南对于晚期病例以及转移或复发患者的首选治疗缺乏一致性。因此，我们的目标是通过合并临床试验数据来创建一个更全面的数据库，评估PD-1抑制剂Dostarlimab在EC中的疗效。方法：我们对Scopus、Medline、Embase和Web of Science数据库进行了全面而系统的检索，确定了Dostarlimab治疗子宫内膜癌的所有符合条件的研究。结果：我们的数据显示，在合并比例的参与者中，OS的风险比为43%。合并EC患者中PFS的风险比为0.39 （95% CI: 0.31-0.49）。总体分析产生的剩余响应概率为72.71% （95% CI: 60.94-84.49%）。此外，将EC患者的两个亚组（包括熟练错配修复（pMMR）和缺陷错配修复（dMMR））的结果汇总，得出ORR为33.93% (95% CI: 21.49-46.37%)， DCR为51.73% （95% CI: 37.0-66.42%）。总的来说，错配修复缺陷组比熟练错配修复组表现出更好的结果。最后，dMMR亚组显示中位PFS为7.86个月（95% CI: 4.46-11.26）。结论：dostarlimumab对pMMR型EC患者疗效有限，但对dMMR型EC患者疗效较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

DARU Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

期刊介绍： DARU Journal of Pharmaceutical Sciences is a peer-reviewed journal published on behalf of Tehran University of Medical Sciences. The journal encompasses all fields of the pharmaceutical sciences and presents timely research on all areas of drug conception, design, manufacture, classification and assessment. The term DARU is derived from the Persian name meaning drug or medicine. This journal is a unique platform to improve the knowledge of researchers and scientists by publishing novel articles including basic and clinical investigations from members of the global scientific community in the forms of original articles, systematic or narrative reviews, meta-analyses, letters, and short communications.